An Open Label, Randomised, Repeat Dose Study to Assess the Pharmacokinetic Performance of Five Ezogabine/Retigabine Modified Release (MR) Formulations at Steady State Compared to the Immediate Release (IR) Formulation.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01332513
Recruitment Status : Completed
First Posted : April 11, 2011
Last Update Posted : May 18, 2018
Information provided by (Responsible Party):

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : May 23, 2011
  Actual Study Completion Date : May 23, 2011